Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Vitamin > Vitamin D

Vitamin D

Vitamin D: An essential nutrient that plays a crucial role in bone health, calcium homeostasis, and immune function.
Discover how PubCompare.ai can optimize your Vitamin D research by enhancing reproducibility and accruacy.
Locate protocols from literature, pre-prints, and patents, while utilizing AI-driven comparisons to identify the best protocols and products.
Streamline your Vitamin D research with PubCompare.ai's powerful tool.

Most cited protocols related to «Vitamin D»

1
Vitamin D and Weight Loss Study
Normal distribution was evaluated with visual inspection of histograms with normal curve, and determination of skewness and kurtosis. All dependent variables except serum OPG and RANKL were considered normally distributed at baseline. After log transformation OPG attained normal distribution and was used as such when parametric statistics were applied. Because of several 0-values (not detectable) RANKL could not be log transformed and therefore was evaluated with non-parametric statistics. The delta values for OPG and RANKL were also not normally distributed and could not be log transformed because of several 0-values, and were therefore evaluated with non-parametric statistics. The other delta values were normally distributed. A multiple linear regression model with age, gender, BMI, smoking status, serum 25(OH)D, serum PTH and serum calcium as covariates was used to evaluate individual predictor of BMD L2-L4, BMD total hip and serum OPG. Correlations were evaluated with Pearson's or Spearman's correlation coefficients as appropriate.
The intervention study was analysed per protocol. Comparisons between the groups at baseline and between their delta values (value at end of the study minus value at baseline) were performed with ANOVA, the Kruskall Wallis test or the Chi-square test. The Bonferroni correction was used where multiple comparisons were performed. Unless otherwise stated, data are expressed as mean ± SD. All tests were done two-sided, and P-value < 0.05 was considered statistically significant. The Statistical Package for Social Sciences version 15.0 was used for all statistical analyses (SPSS Inc., Chicago, Ill., USA).
The power calculation was performed according to the primary end point (weight loss) to disclose a clinically significant difference of 6 kg with or without vitamin D supplementation [16 (link)].
Jorde R., Sneve M., Torjesen P.A., Figenschau Y., Hansen J.B, & Grimnes G. (2010). No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year. Nutrition Journal, 9, 1.
Full text: Click here
Publication 2010
Calcium, Dietary Gender neuro-oncological ventral antigen 2, human Serum TNFSF11 protein, human Vitamin D
2
KDIGO Controversies Conference on CKD-MBD

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Adult ARID1A protein, human Bones Calcium Cardiovascular System Chronic Kidney Disease-Mineral and Bone Disorder Conferences Diagnosis Grafts Phosphates System, Endocrine Vascular Calcification Vitamin D
3
Calcilytic Compound Effects on Calcium Homeostasis
Nuf mice were maintained on the inbred 102/H background, which is a substrain bred at the Mary Lyon Centre. Mice were kept in accordance with United Kingdom Home Office welfare guidance and project license restrictions. Mice were fed ad libitum on a commercial diet (which contained 1.2% calcium, 0.8% phosphate, and 3000-IU/kg vitamin D; Rat and Mouse Diet No. 3; Special Diet Services). A single bolus of NPS 2143 or vehicle (15% aqueous solution of 2-hydroxypropyl-β-cyclodextrin) was administered by ip injection to wild-type, Nuf/+, and Nuf/Nuf mice aged between 16 and 20 weeks (n = 8–14 for all groups). An aqueous solution of 2-hydroxypropyl-β-cyclodextrin was used as the drug vehicle for NPS 2143, because this has previously been demonstrated to be effective at dissolving this calcilytic compound and to be safe and well tolerated in rodent studies (15 (link), 16 (link), 28 (link)). Based on the findings of previous rodent studies involving NPS 2143 (16 (link), 28 (link)), a dose of 30 mg/kg was administered to wild-type and Nuf mice. Plasma samples were obtained at either 0, 1, 4, or 24 hours by tail vein or terminal bleed. Urine samples were obtained from untreated mice or mice that had been bled at 1 hour after administration of NPS 2143 or drug vehicle alone and then immediately housed in metabolic cages (Tecniplast) for a 24-hour period and fed ad libitum on water and powdered chow (29 (link)). Urine samples were analyzed for calcium and creatinine and plasma samples analyzed for total calcium, albumin, sodium, potassium, phosphate, urea, creatinine, and alkaline phosphatase activities using a Beckman Coulter AU680 analyzer, as previously described (29 (link)). Plasma calcium was adjusted for albumin using the formula: ((albumin-mean albumin) × 0.02) + calcium, as reported (29 (link)). The calcium to creatinine clearance ratio (CCCR) was calculated using the formula UCa/PCa × PCr/UCr, where UCa is the urinary concentration of calcium in mmol/L, PCa is the plasma concentration of adjusted calcium in mmol/L, UCr is the urinary concentration of creatinine in mmol/L, and PCr is the plasma concentration of creatinine in mmol/L (29 (link)). Plasma PTH concentrations were determined using an ELISA for mouse intact PTH (Immutopics), as described (30 (link)).
Hannan F.M., Walls G.V., Babinsky V.N., Nesbit M.A., Kallay E., Hough T.A., Fraser W.D., Cox R.D., Hu J., Spiegel A.M, & Thakker R.V. (2015). The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1). Endocrinology, 156(9), 3114-3121.
Full text: Click here
Publication 2015
Albumins Alkaline Phosphatase Calcium, Dietary Creatinine Cyclodextrins Diet Dietary Services Enzyme-Linked Immunosorbent Assay Hypromellose Injections, Intraperitoneal Mice, House NPS 2143 Pharmaceutical Vehicles Phosphates Plasma Potassium Rodent Sodium Tail Urea Urine Veins Vitamin D
4
Dietary Intake Assessment in Young Women

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Calcium, Dietary calcium orange Dietary Supplements Dietitian Eating Ergocalciferol Food Nutrient Intake Nutrients Vitamin D Woman
5
Vitamin D Deficiency Induction in Rats
Ten male Wistar rats (Harlan CPB, Horst, Netherlands), aged 9-10 weeks, weighing 300–325 grams at the beginning of the study were used. The rats underwent one-week acclimatization to the animal facility prior to the induction of vitamin D deficiency. Animals were maintained under conventional housing conditions and were given food and water ad libitum. From day one of the experiment, the rats were fed a vitamin D deficient diet (TD.87095 Brown C.C. Vit.D Defic, containing 20% lactose, 2% Ca, and 1.25% P). To induce CYP24A1 expression, to accelerate the catabolism of endogenous 25D and calcitriol stores, the rats received intraperitoneal injections of 32 ng of 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol; Zemplar, kindly provided by AbbVie) on days 1, 3, 5, 8, 10, and 12. The rats were weighed on days 1, 10, 15, and 22 during the induction of vitamin D deficiency. Food consumption was measured every day. The experimental protocol was approved by the Animal Care Committee at the VU University Medical Center, Amsterdam.
Stavenuiter A.W., Arcidiacono M.V., Ferrantelli E., Keuning E.D., Vila Cuenca M., ter Wee P.M., Beelen R.H., Vervloet M.G, & Dusso A.S. (2015). A Novel Rat Model of Vitamin D Deficiency: Safe and Rapid Induction of Vitamin D and Calcitriol Deficiency without Hyperparathyroidism. BioMed Research International, 2015, 604275.
Full text: Click here
Publication 2015
Acclimatization Animal Care Committees Animals Calcitriol Catabolism Diet Food Injections, Intraperitoneal Lactose Males paricalcitol Rats, Wistar Rattus norvegicus Vitamin D Vitamin D3 24-Hydroxylase Vitamin D Deficiency Zemplar

Most recents protocols related to «Vitamin D»

1
Silicic Acid and Mineral Supplementation Protocol
Not available on PMC !

Example 6

    • Daily oral administration of 5 mg of bioavailable silicic acid in the form of choline-stabilized orthosilicic acid (ch-OSA®), wherein silicic acid is stabilized with choline chloride, for instance in the form of a capsule;
    • Daily administration of 1000 mg calcium, 6 microgram vitamin D, 50 microgram vitamin K, preferably in two formulations, such as tablets;
    • Daily administration of 200 mg vitamin C, 100 microgram selenium, 10 mg zinc, 1 mg copper, 0.5 mg boron, 200 mg magnesium, for instance in the form of a single formulation, such as a tablet.

    • 6 months oral administration of 10 mg of a bioavailable silicon compound per day, which bioavailable silicon compound is in the form of choline-stabilized orthosilicic acid (ch-OSA®), wherein silicic acid is stabilized with choline chloride; 10 mg bioavailable silicon is preferably administered as two dosage units, each containing 5 mg bioavailable silicon, for instance as a tablet;
    • mouth rinsing with chlorhexidine 1% solution twice daily during 4 weeks.

It is herein preferable, that the administration of the bioavailable silicic acid and the mouth rinsing start simultaneously.

US11878031B2. Silicic acids for use in the treatment of periodontitis (2024-01-23). Bio Minerals N.V. [BE]. Inventors: Mario Remi Yvonne Calomme [BE], Kathleen Jozef Ingrid Suzanne Van Hoof [BE].
Full text: Click here
Patent 2024
Acids Administration, Oral Ascorbic Acid Boron Calcium, Dietary Capsule Chlorhexidine Choline Choline Chloride Copper Magnesium Periodontitis Selenium Silicic acid Silicon Tablet Vitamin D Vitamin K Zinc
2
Effects of Vitamin D and BPA on Mice
The animals were randomly divided into control and treated groups 12 mice in each (six males and six females). The control groups were further divided into sham (no treatment) and vehicle (sterile corn oil), whereas the treatment group was divided into VitD (2,195 IU/kg), BPA (50 μg/kg), and BPA+VitD (50 μg/kg + 2,195 IU/kg) groups. The BPA and VitD doses were administered based on previously recommended doses [23 (link)–27 (link)]. Corn oil, VitD, and BPA were administrated daily, intraperitoneally (i.p), for six weeks. One week later, at 10.5 weeks old, animals were sacrificed, and blood and spleen samples were collected for biochemical and histological examinations (Fig 1).
The mice were administered intraperitoneally with 50 μg VitD, 2195 IU BPA/kg body weight, either alone or in combination, respectively, for six weeks.
Al-Griw M.A., Balog H.N., Shaibi T., Elmoaket M.F., AbuGamja I.S., AlBadawi A.B., Shamlan G., Alfarga A., Eskandrani A.A., Alnajeebi A.M., Babteen N.A., Alansari W.S, & Alghazeer R. (2023). Therapeutic potential of vitamin D against bisphenol A-induced spleen injury in Swiss albino mice. PLOS ONE, 18(3), e0280719.
Full text: Click here
Publication 2023
Animals BLOOD Body Weight Corn oil Females Males Mice, House Physical Examination Spleen Sterility, Reproductive Vitamin D
3
Olanzapine and Vitamin D Exposure
Electronic medical records were obtained from the Nihon University School of Medicine’s Clinical Data Warehouse (NUSM’s CDW). This database includes detailed diagnostic, demographic, and laboratory data for inpatients and outpatients. We received written informed consent and agreement for the secondary use after anonymization at three hospitals affiliated with the NUSM (Nagashima et al., 2022 (link)). Similar to the JMDC claims data analysis, the pre-prescription period of olanzapine was defined as the period within 12 months of the first prescription. Contrastingly, the post-prescription period was defined as the period within 12 months after initiating olanzapine treatment. Among them, preceding users of vitamin D were defined as patients whose first prescription of vitamin D was ahead of the first prescription of olanzapine for at least 1 day. Matching was not performed in this study because there were no significant differences in the baseline characteristics (Table 3). The blood laboratory values were extracted from the database, and the baseline value (month 0) was selected from the nearest test prior to the first prescription of olanzapine. The values at each checkpoint (months 3, 6, 9, and 12) were selected from the furthest test results from the first prescription of olanzapine. The missing values were imputed using the last observation carried forward method. An unpaired two-tailed t-test with Welch’s correction for continuous variables and Fisher’s exact test for categorical data were conducted to compare the differences in baseline characteristics between patients with or without vitamin D exposure.
Zhou Z., Nagashima T., Toda C., Kobayashi M., Suzuki T., Nagayasu K., Shirakawa H., Asai S, & Kaneko S. (2023). Vitamin D supplementation is effective for olanzapine-induced dyslipidemia. Frontiers in Pharmacology, 14, 1135516.
Full text: Click here
Publication 2023
BLOOD Cell Cycle Checkpoints Diagnosis Inpatient Olanzapine Outpatients Patients Vitamin D
4
Olanzapine and Vitamin D Impact on Metabolic Profile
Insurance claims data collected by JMDC Inc. from January 2005 to March 2018 were purchased, which contained the medical and prescription claims of 5,550,241 individuals and their dependents on a monthly basis. Health checkup data, including blood test results, body mass index (BMI), and waist circumferences, were provided by 2,278,697 individuals. The patients were mainly aged ≤ 65 years, and no patients aged ≥ 75 years were included. The drug names were coded using the Anatomical Therapeutic Chemical Classification System.
On retrospectively analyzing the profile of the first event onsets, the users of olanzapine were identified as those who were prescribed olanzapine more than 2 months after being included in the JMDC claims database. Patients without specific health checkup data were also excluded. Thus, 1,853 patients with olanzapine were included in the present study. Among them, vitamin D users were defined as patients whose first prescription of vitamin D was ahead of olanzapine treatment. The pre-prescription period for olanzapine was defined as the period within 12 months, while the post-prescription period was defined as the period within 12 months after initiating olanzapine treatment.
The blood test results included in the present study were triglyceride, LDL cholesterol, and high-density lipoprotein (HDL) cholesterol levels apart from BMI and waist circumstances. Test results were collected for each individual on the nearest date before initiating olanzapine treatment in the pre-prescription period and on the closest date in the post-prescription period after initiating olanzapine treatment. To reduce bias in population backgrounds, the propensity score matching method (greedy 1:1 matching) was used by balancing covariates between settings. The propensity score for vitamin D was obtained by fitting a logistic regression model that included all covariates of interest (Table 2). The propensity score of each patient with or without vitamin D treatment was subsequently matched using the nearest neighbor method. Using the matched outcomes, an unpaired two-tailed t-test with Welch’s correction for continuous variables and Fisher’s exact test for categorical data were conducted to compare the differences in baseline characteristics between patients with or without vitamin D exposure.
Zhou Z., Nagashima T., Toda C., Kobayashi M., Suzuki T., Nagayasu K., Shirakawa H., Asai S, & Kaneko S. (2023). Vitamin D supplementation is effective for olanzapine-induced dyslipidemia. Frontiers in Pharmacology, 14, 1135516.
Full text: Click here
Publication 2023
Cholesterol, beta-Lipoprotein Hematologic Tests High Density Lipoprotein Cholesterol Index, Body Mass Olanzapine Patients Pharmaceutical Preparations Triglycerides Vitamin D Waist Circumference
5
Comprehensive Profiling of UC Patient Data
The potential parameters were considered based on accessibility and clinical simplicity. Data of UC patients were collected from the electronic medical database of our center, including general demographic and clinical characteristics: sex, age (year), body mass index (kg/m2), age of onset (year), fever (temperature ≥37.3°C), abdominal pain and hematochezia, stool frequency, complications or comorbidities; Blood biomarkers: Vit D (ng/ml), folate (ng/ml), vitamin B12 (pg/ml), ALB (g/L) prealbumin (PAB, mg/L), retinol-binding protein (mg/L), ferritin (ng/mL), Fbg (g/L), white blood cell count (*109/L), neutrophil count (*109/L), monocyte count (*109/L), lymphocyte count (*109/L), platelet count (*109/L), hemoglobin (g/L) and erythrocyte sedimentation rate (mm/H), and fecal occult blood test. All predictors were collected within 1 week before or after colonoscopy.
Li X., Tang Z., Liu Y., Zhu X, & Liu F. (2023). Risk prediction model based on blood biomarkers for predicting moderate to severe endoscopic activity in patients with ulcerative colitis. Frontiers in Medicine, 10, 1101237.
Full text: Click here
Publication 2023
Abdominal Pain Biological Markers BLOOD Cobalamins Colonoscopy Fecal Occult Blood Test Feces Ferritin Fever Folate Hematochezia Hemoglobin Index, Body Mass Leukocyte Count Lymphocyte Count Monocytes Neutrophil Patients Platelet Counts, Blood Prealbumin Retinol Binding Proteins Sedimentation Rates, Erythrocyte Vitamin D

Top products related to «Vitamin D»

1
Advia centaur by Siemens
Sourced in Germany, United States, United Kingdom, Spain, Ireland, Australia, Italy, Austria
The ADVIA Centaur is a fully automated, random-access immunoassay analyzer designed to perform a wide range of immunoassay tests. It is capable of processing multiple sample types, including serum, plasma, and urine. The instrument uses chemiluminescent technology to detect and quantify analytes in the samples.
2
Cobas 6000 by Roche
Sourced in Switzerland, Germany, United States, Japan, Denmark, Italy, France, United Kingdom, Belgium, Norway, China, Israel, Poland, Netherlands, Sweden
The Cobas 6000 is an automated clinical chemistry and immunoassay analyzer system designed for high-volume laboratory testing. It combines the features of two separate instruments, the Cobas c 501 module for clinical chemistry and the Cobas e 601 module for immunoassays, into a single integrated platform. The Cobas 6000 system is capable of performing a wide range of diagnostic tests, including biochemical, immunological, and specialty assays.
3
Cobas e411 by Roche
Sourced in Germany, Switzerland, United States, Japan, United Kingdom, Denmark, France, Poland
The Cobas e411 is a compact and fully automated immunoassay analyzer designed for clinical laboratory settings. It is capable of performing a wide range of immunoassay tests, including those for hormones, therapeutic drug monitoring, and infectious disease markers. The Cobas e411 is known for its reliability, ease of use, and efficient throughput.
4
Cobas 8000 by Roche
Sourced in Switzerland, Germany, United States, Japan, France, Italy, China, United Kingdom, Sweden
The Cobas 8000 is a modular, automated in-vitro diagnostic system designed for high-throughput clinical chemistry and immunochemistry testing. It is used to perform a wide range of laboratory tests, including those for chemistry, immunoassay, and electrolyte analysis. The Cobas 8000 is capable of processing a large volume of samples efficiently and accurately.
5
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
6
Liaison 25 oh vitamin d total assay by DiaSorin
Sourced in Italy, United States
The LIAISON® 25 OH Vitamin D TOTAL Assay is a laboratory equipment product developed by DiaSorin. The core function of this assay is to quantitatively determine the total 25-hydroxyvitamin D concentration in human serum and plasma samples.
7
Liaison xl by DiaSorin
Sourced in Italy, Germany, United States, United Kingdom, France
The Liaison XL is a fully automated chemiluminescence immunoassay (CLIA) analyzer developed by DiaSorin. It is designed for the detection and quantification of various analytes in clinical laboratory settings. The Liaison XL performs automated sample processing, reagent handling, and result reporting, providing efficient and reliable diagnostic testing.
8
Advia centaur xp by Siemens
Sourced in Germany, United States, Switzerland, Ireland, China, Japan, Croatia, United Kingdom, Sweden
The ADVIA Centaur XP is an automated immunoassay analyzer designed for in vitro diagnostic testing. It is capable of performing a wide range of immunoassay tests, including those for hormones, cardiac markers, infectious diseases, and more. The system features advanced automation and processing capabilities to enable efficient and high-throughput testing.
9
Cobas e411 analyzer by Roche
Sourced in Germany, Switzerland, United States, Japan, France
The Cobas e411 analyzer is a fully automated, random-access immunoassay analyzer designed for clinical diagnostics. It is capable of performing a variety of immunoassay tests to aid in the diagnosis and monitoring of various medical conditions.

More about "Vitamin D"

Vitamin D is a crucial nutrient that plays a vital role in maintaining bone health, calcium regulation, and immune function.
Also known as the 'sunshine vitamin,' it is primarily obtained through sun exposure, but can also be acquired through dietary sources such as fatty fish, egg yolks, and fortified foods.
Measuring and monitoring vitamin D levels is essential for understanding an individual's overall health status.
Several laboratory instruments, including the ADVIA Centaur, Cobas 6000, Cobas e411, Cobas 8000, and LIAISON® 25 OH Vitamin D TOTAL Assay, are commonly used to analyze and quantify vitamin D levels in the blood.
Optimizing vitamin D research is crucial for advancing our understanding of its diverse physiological effects.
PubCompare.ai, a powerful tool, can assist researchers in streamlining their vitamin D studies by enhancing reproducibility and accuracy.
The platform allows users to locate protocols from literature, pre-prints, and patents, while utilizing AI-driven comparisons to identify the best protocols and products.
By incorporating synonyms, related terms, and key subtopics, such as cholecalciferol, ergocalciferol, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, calcitriol, and vitamin D deficiency, researchers can enhance their understanding of the multifaceted aspects of vitamin D.
Additionally, leveraging the capabilities of instruments like the Liaison XL, ADVIA Centaur XP, and Cobas e411 analyzer can provide valuable insights into the measurement and analysis of vitamin D levels.
Ultimately, a comprehensive understanding of vitamin D and the tools available for its research can lead to improved healthcare outcomes, with potential benefits for bone health, immune function, and overall well-being.
By utilizing the insights and resources provided by PubCompare.ai, researchers can streamline their vitamin D studies and drive advancements in this crucial area of health and wellness.